SCHEMBL8212475

SCHEMBL8212475

Cn1nnc(-c2ccc(O)c(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 3/20 0.43
LRRK2 Q5S007 1/20 0.43
AR P10275 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
ESR1 P03372 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PRKCZ Q05513 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13846207 0.85 LRRK2 (0.46) LRRK2KDM2BKDM4CNPC1NFKB1
SCHEMBL6609423 0.82 TRPV1 (0.42) ESR2ARTRPV1ESR1NPC1
SCHEMBL15650550 0.81 ALDH1A1 (0.48) ESR2LRRK2KDM2BKDM4CNPC1
SCHEMBL5058907 0.79 ALDH1A1 (0.42) LRRK2KDM2BKDM4CNPC1RAB9A
SCHEMBL5064586 0.79 XDH (0.49) LRRK2KDM2BKDM4CNPC1RAB9A
SCHEMBL8211774 0.78 HRH4 (0.49) LRRK2TRPV1ALDH1A1
SCHEMBL13838574 0.78 KDM2B (0.42) LRRK2KDM2BKDM4CNPC1NFKB1
SCHEMBL13729002 0.77 KDM2B (0.41) LRRK2KDM2BKDM4CNPC1NFKB1
SCHEMBL2611134 0.75 KMT2A (0.54) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL851750 0.75 NPC1 (0.52) KDM4CESR1NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021733-A2 TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed